Toshiyuki Officer Resi Hamaoka

Toshiyuki Officer Resi Hamaoka's AcademicInfluence.com Rankings

Biology

#10043

World Rank

#13327

Historical Rank

Immunology

#621

World Rank

#641

Historical Rank

biology Degrees

Download Badge

Biology

Toshiyuki Officer Resi Hamaoka's Degrees

PhD Immunology University of Tokyo
Doctorate Medicine University of Tokyo

Why Is Toshiyuki Officer Resi Hamaoka Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Toshiyuki Officer Resi Hamaoka's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Identification of a T cell-derived b cell growth factor distinct from interleukin 2 (1982) (1027)
Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long- term bone marrow cultures (1990) (598)
A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. (1997) (355)
CELL INTERACTIONS BETWEEN HISTOINCOMPATIBLE T AND B LYMPHOCYTES (1973) (336)
Essential role for ERK2 mitogen‐activated protein kinase in placental development (2003) (301)
Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. (1988) (280)
Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. (1991) (273)
Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. (1995) (238)
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. (1997) (220)
A Novel Function of Vα14+CD4+NKT Cells: Stimulation of IL-12 Production by Antigen-Presenting Cells in the Innate Immune System (1999) (218)
Synergy of IL-12 and IL-18 for IFN-γ Gene Expression: IL-12-Induced STAT4 Contributes to IFN-γ Promoter Activation by Up-Regulating the Binding Activity of IL-18-Induced Activator Protein 11 (2002) (214)
Cell interactions between histoincompatible T and B lymphocytes. The H-2 gene complex determines successful physiologic lymphocyte interactions. (1973) (213)
CELL INTERACTIONS BETWEEN HISTOINCOMPATIBLE T AND B LYMPHOCYTES (1973) (196)
Non-CD28 Costimulatory Molecules Present in T Cell Rafts Induce T Cell Costimulation by Enhancing the Association of TCR with Rafts1 (2000) (179)
The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. (1984) (167)
Antigen-induced T cell-replacing factor (TRF). III. Establishment of T cell hybrid clone continuously producing TRF and functional analysis of released TRF. (1980) (159)
Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. (1995) (156)
Plasma cholecystokinin responses after ingestion of liquid meal and intraduodenal infusion of fat, amino acids, or hydrochloric acid in man: analysis with region specific radioimmunoassay. (1983) (151)
A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. (1998) (145)
Differential capacities of CD4+, CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. (1998) (143)
A non‐peptide CCR5 antagonist inhibits collagen‐induced arthritis by modulating T cell migration without affecting anti‐collagen T cell responses (2002) (139)
CELL INTERACTIONS BETWEEN HISTOINCOMPATIBLE T AND B LYMPHOCYTES (1973) (138)
Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. (2002) (133)
Cutting Edge: Fyn Is Essential for Tyrosine Phosphorylation of Csk-Binding Protein/Phosphoprotein Associated with Glycolipid-Enriched Microdomains in Lipid Rafts in Resting T Cells1 (2002) (130)
Involvement of SHP-1 tyrosine phosphatase in TCR-mediated signaling pathways in lipid rafts. (2001) (124)
Induction of the chemokine receptor CXCR3 on TCR‐stimulated T cells: dependence on the release from persistent TCR‐triggering and requirement for IFN‐γ stimulation (2002) (124)
Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody response. (1982) (123)
The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3 (2003) (118)
IMMUNOLOGICAL TOLERANCE IN BONE MARROW-DERIVED LYMPHOCYTES (1972) (117)
Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. (1997) (112)
Antigen-induced T cell-replacing factor (TRF). I. Functional characterization of a TRF-producing helper T cell subset and genetic studies on TRF production. (1980) (109)
Identification of a Novel Transmembrane Semaphorin Expressed on Lymphocytes* (1996) (107)
Regulation of T cell‐dependent and ‐independent IL‐12 production by the three Th2‐type cytokines IL‐10, IL‐6, and IL‐4 (1997) (103)
HAPTEN-SPECIFIC IgE ANTIBODY RESPONSES IN MICE (1973) (103)
A role for CD9 molecules in T cell activation (1996) (100)
Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis (1984) (96)
Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity response to alloantigens by portal venous inoculation with allogeneic cells. (1985) (91)
Ontogeny of cholecystokinin‐8‐containing neuron system of the rat: An immunohistochemical analysis. I. Forebrain and upper brainstem (1983) (91)
A Role of Interferon-γ (IFN-γ) in Tumor Immunity: T Cells with the Capacity to Reject Tumor Cells Are Generated But Fail to Migrate to Tumor Sitesin IFN-γ-deficient Mice (2001) (87)
Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor growth inhibition induced during tumor immunotherapy with rIL-12 (1996) (87)
Soluble factors involved in B cell differentiation: identification of two distinct T cell-replacing factors (TRF). (1983) (87)
Hapten-specific IgE antibody responses in mice. I. Secondary IgE responses in irradiated recipients of syngeneic primed spleen cells. (1973) (83)
Cellular site of action of various adjuvants in antibody responses to hapten-carrier conjugates. (1973) (83)
The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes. (1980) (82)
A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. (1999) (80)
The occurrence of cholecystokinin-like immunoreactive neurons in the rat neostriatum: light and electron microscopic analysis (1984) (78)
Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. (1989) (77)
Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity. (1992) (76)
Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis. (1989) (76)
Dynamic changes in the mobility of LAT in aggregated lipid rafts upon T cell activation (2003) (76)
High plasma cholecystokinin levels in patients with chronic pancreatitis having abdominal pain. (1986) (74)
An Absolute Requirement for STAT4 and a Role for IFN-γ as an Amplifying Factor in IL-12 Induction of the Functional IL-18 Receptor Complex1 (2001) (74)
Induction of B cell differentiation by T cell factors. I. Stimulation of IgM secretion by products of a T cell hybridoma and a T cell line. (1981) (71)
Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis. (1988) (71)
IL-12 produced by antigen-presenting cells induces IL-2-independent proliferation of T helper cell clones. (1996) (70)
Immunologic abnormality in NZB/NZW F1 mice. Thymus-independent occurrence of B cell abnormality and requirement for T cells in the development of autoimmune disease, as evidenced by an analysis of the athymic nude individuals. (1988) (70)
Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway (2000) (69)
Purification and physicochemical characterization of murine T cell replacing factor (TRF). (1985) (69)
Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. (1990) (69)
Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. (1997) (67)
Expression of an inducible type of nitric oxide (NO) synthase in the thymus and involvement of NO in deletion of TCR-stimulated double-positive thymocytes. (1997) (66)
A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. (2001) (65)
Multiple Roles of Interferon-γ in the Mediation of Interleukin 12-induced Tumor Regression (1998) (64)
Distribution, origin, and fine structures of cholecystokinin-8-like immunoreactive terminals in the nucleus ventromedialis hypothalami of the rat (1984) (62)
IL‐12‐induced tumor regression correlates with in situ activity of IFN‐γ produced by tumor‐infiltrating cells and its secondary induction of anti‐tumor pathways (1997) (60)
Expression of VLA-4 on thymocytes. Maturation stage-associated transition and its correlation with their capacity to adhere to thymic stromal cells. (1992) (58)
Role of glycosaminoglycans in the regulation of T cell proliferation induced by thymic stroma-derived T cell growth factor. (1991) (57)
Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. (1996) (57)
Tolerance induction of allo-class II H-2 antigen-reactive L3T4+ helper T cells and prolonged survival of the corresponding class II H-2-disparate skin graft. (1989) (56)
CD9-mediated costimulation of TCR-triggered naive T cells leads to activation followed by apoptosis. (1997) (56)
Phenotypically and functionally distinct T-cell subsets in anti-tumor responses. (1987) (56)
A fundamental difference in the capacity to induce proliferation of naive T cells between CD28 and other co‐stimulatory molecules (1998) (56)
Translocation of tyrosine-phosphorylated TCRzeta chain to glycolipid-enriched membrane domains upon T cell activation. (1999) (56)
Reduction of Glycosphingolipid Levels in Lipid Rafts Affects the Expression State and Function of Glycosylphosphatidylinositol-anchored Proteins but Does Not Impair Signal Transduction via the T Cell Receptor* (2003) (55)
B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions. (1997) (54)
Protection from anti-TCR/CD3-induced apoptosis in immature thymocytes by a signal through thymic shared antigen-1/stem cell antigen-2 (1996) (53)
A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. (2002) (53)
Hapten-specific IgE antibody responses in mice. IV. Evidence for distinctive sensitivities of IgE and IgG B lymphocytes to the regulatory influence of T cells. (1974) (52)
IMMUNOLOGICAL TOLERANCE IN BONE MARROW-DERIVED LYMPHOCYTES III. TOLERANCE INDUCTION IN PRIMED B CELLS BY HAPTEN CONJUGATES OF UNRELATED IMMUNOGENIC OR NONIMMUNOGENIC CARRIERS (1974) (52)
Studies on the induction of tolerance to alloantigens. II. The generation of serum factor(s) able to transfer alloantigen-specific tolerance for delayed-type hypersensitivity by portal venous inoculation with allogeneic cells. (1986) (52)
Association of a tetraspanin CD9 with CD5 on the T cell surface: role of particular transmembrane domains in the association. (1999) (51)
A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. (1999) (51)
Regulation of B-cell differentiation: interactions of factors and corresponding receptors. (1986) (51)
A critical role for IL‐12 in CCR5 induction on T cell receptor‐triggered mouse CD4+ and CD8+ T cells (2001) (51)
Radioresistance of carrier-specific helper thymus-derived lymphocytes in mice. (1972) (50)
Modulation of TCR-mediated signaling pathway by thymic shared antigen-1 (TSA-1)/stem cell antigen-2 (Sca-2). (1995) (50)
Inhibition of Growth and Metastasis of Ovarian Carcinoma by Administering a Drug Capable of Interfering with Vascular Endothelial Growth Factor Activity (1996) (49)
The augmentation of tumor‐specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus‐reactive helper T cells (1984) (48)
Induction of Insulitis by Adoptive Transfer With L3T4+ Lyt2− T-Lymphocytes in T-Lymphocyte–Depleted NOD Mice (1988) (48)
Selective suppression of t‐cell activity in tumor‐bearing mice and its improvement by lentinan, a potent anti‐tumor polysaccharide (1976) (48)
A pivotal role of cysteine 3 of Lck tyrosine kinase for localization to glycolipid-enriched microdomains and T cell activation. (2001) (48)
Direct suppression of TCR-mediated activation of extracellular signal-regulated kinase by leukocyte protein tyrosine phosphatase, a tyrosine-specific phosphatase. (1999) (46)
Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten- reactive T lymphocytes (1979) (45)
Requirement for IFN-γ in IL-12 production induced by collaboration between Vα14+ NKT cells and antigen-presenting cells (2000) (45)
IL-12 as Well as IL-2 Upregulates CCR5 Expression on T Cell Receptor-Triggered Human CD4+ and CD8+ T Cells (2001) (44)
A Mandatory Role for STAT4 in IL-12 Induction of Mouse T Cell CCR51 (2001) (43)
Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression. (1984) (43)
Establishment of an IL‐12‐responsive T cell clone: its characterization and utilization in the quantitation of IL‐12 activity (1997) (42)
Establishment of highly specific radioimmunoassays for neurokinin A and neurokinin B and determination of tissue distribution of these peptides in rat central nervous system (1989) (42)
Ig RNA expression in normal B cells stimulated with anti-IgM antibody and T cell-derived growth and differentiation factors (1984) (41)
Transforming Growth Factor‐β CD4+ T cells Tumor‐bearing state Immunosuppression Enhanced Production of TGF‐β and a Progressive Increase in TGF‐β Susceptibility of Anti‐tumor CD4+ T Cell Function (1993) (41)
Hapten-specific IgE antibody responses in mice. 3. Establishment of parameters for generation of helper T cell function regulating the primary and secondary responses of IgE and IgG B lymphocytes. (1974) (40)
Low plasma cholecystokinin response after ingestion of a test meal in patients with chronic pancreatitis. (1985) (40)
Differentiation of thymocytes from CD3-CD4-CD8- through CD3-CD4-CD8+ into more mature stages induced by a thymic stromal cell clone. (1990) (40)
Activation-induced expression of thymic shared antigen-1 on T lymphocytes and its inhibitory role for TCR-mediated IL-2 production. (1994) (39)
The requirement of Ia-positive accessory cells for the induction of hapten-reactive cytotoxic T lymphocytes in vitro. (1979) (39)
The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells. (1985) (38)
Role of the thymus in repopulating alloantigen-reactive T cells after its functional elimination by intravenous presensitization with allogeneic cells. (1991) (37)
Requirement for distinct Janus kinases and STAT proteins in T cell proliferation versus IFN-gamma production following IL-12 stimulation. (1998) (37)
Cellular and Molecular Mechanisms Underlying IL‐12‐Induced Tumor Regression (1996) (36)
Differential requirements for JAK2 and TYK2 in T cell proliferation and IFN‐γ production induced by IL‐12 alone or together with IL‐18 (2003) (36)
Molecular Mechanisms Underlying Differential Contribution of CD28 Versus Non-CD28 Costimulatory Molecules to IL-2 Promoter Activation1 (2002) (35)
Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages. (1985) (35)
The augmentation of tumor‐specific immunity by virus help. I. Demonstration of vaccinia virus‐reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses (1984) (35)
Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. III. Analysis of regulatory cells suppressing the induction of thyroiditis. (1990) (35)
A novel vaccine delivery system using immunopotentiating fusogenic liposomes. (1999) (34)
Potentiation of helper T cell function in IgE antibody responses by bacterial lipolysaccharide (LPS). (1974) (34)
Antitumor and antimetastatic effects of interleukin 12 (1996) (33)
Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system. (1984) (33)
Inactivation of mitogen-activated protein kinases by a mammalian tyrosine-specific phosphatase, PTPBR7. (1999) (33)
Induction of immunological tolerance in bone marrow-derived lymphocytes of the IgE antibody class. (1973) (32)
B cell response pathways regulated by IL-5 and IL-2. Secretory microH chain-mRNA and J chain mRNA expression are separately controlled events. (1989) (31)
Polyclonal B cell activation by a B cell differentiation factor, B151-TRF2. III. B151-TRF2 as a B cell differentiation factor closely associated with autoimmune disease. (1987) (30)
Small and large B cells respond differently to T cell-derived B cell growth and differentiation factors. (1985) (30)
Particular types of tumor cells have the capacity to convert transforming growth factor beta from a latent to an active form. (1992) (30)
Antibody production in mice: IV. The suppressive effect of anti-hapten and anti-carrier antibodies on the recognition of hapten-carrier conjugate in the secondary response (1971) (29)
Studies on the induction of tolerance to alloantigens. III. Induction of antibodies directed against alloantigen-specific delayed-type hypersensitivity T cells by a single injection of allogeneic lymphocytes via portal venous route. (1988) (29)
The Activation of L3T4+ Helper T Cells Assisting the Generation of Anti‐Tumor Lyt‐2+ Cytotoxic T Lymphocytes: Requirement of 1a‐Positive Antigen‐Presenting Cells for Processing and Presentation of Tumor Antigens (1987) (28)
Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts. (1991) (28)
Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state (1995) (28)
Antigen-induced T cell-replacing factor (TRF). II. X-linked gene control for the expression of TRF-acceptor site(s) on B lymphocytes and preparation of specific antiserum to that acceptor. (1980) (28)
Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy (1988) (28)
Serine 6 of Lck Tyrosine Kinase: A Critical Site for Lck Myristoylation, Membrane Localization, and Function in T Lymphocytes1 (2000) (28)
Induction of surface CCR4 and its functionality in mouse Th2 cells is regulated differently during Th2 development (2005) (28)
A novel immunization procedure for production of anti-cholecystokinin-specific antiserum of low cross-reactivity. (1981) (28)
IL‐12 plays a pivotal role in LFA‐1‐mediated T cell adhesiveness by up‐regulation of CCR5 expression (2001) (27)
The role of tumor-specific Lyt-1+2− T cells in eradicating tumor cells in vivo (1987) (27)
DBA/2Ha Mice as a Model of an X‐Linked Immunodeficiency which is Defective in the Expression of TRF‐Acceptor Site(s) on B Lymphocytes (1982) (26)
A mechanism underlying STAT4‐mediated up‐regulation of IFN‐γ induction inTCR‐triggered T cells (2004) (26)
IMMUNOLOGICAL TOLERANCE IN BONE MARROW-DERIVED LYMPHOCYTES : II. EFFECTS OF ALLOGENEIC CELL INTERACTIONS AND ENZYMATIC DIGESTION WITH TRYPSIN ON INACTIVATED HAPTEN-SPECIFIC PRECURSORS OF ANTIBODY-FORMING CELLS (1974) (26)
Heterogenous graft rejection pathways in class I major histocompatibility complex-disparate combinations and their differential susceptibility to immunomodulation induced by intravenous presensitization with relevant alloantigens (1991) (25)
HAPTEN-SPECIFIC IgE ANTIBODY RESPONSES IN MICE (1973) (25)
Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. I. Detection and characterization of hapten-reactive suppressor T-cell activity in mice immunized with hapten-isologous protein conjugate (1977) (25)
Characterization of an immune response gene in mice controlling IgE and IgG antibody responses to ragweed pollen extract and its 2,4‐dinitrophenylated derivative (1974) (24)
Coordination of chemokine and adhesion systems in intratumoral T cell migration responsible for the induction of tumor regression. (2001) (24)
CD5 Costimulation Up-Regulates the Signaling to Extracellular Signal-Regulated Kinase Activation in CD4+CD8+ Thymocytes and Supports Their Differentiation to the CD4 Lineage1 (2000) (24)
A sequence of cellular and molecular events involved in IL12-induced tumour regression. (1995) (23)
TOLERANCE INDUCTION OF ALLOREACTIVITY BY PORTAL VENOUS INOCULATION WITH ALLOGENEIC CELLS FOLLOWED BY THE INJECTION OF CYCLOPHOSPHAMIDE: I. SPECIFIC SUPPRESSION OF ALLOREACTIVE CYTOTOXIC AND DELAYED‐TYPE HYPERSENSITIVITY RESPONSES AS WELL AS ALLOGRAFT REJECTION (1987) (23)
Mechanism of adjuvant activity of poly A:U on antibody responses to hapten-carrier conjugates. (1973) (23)
Thymic stroma-derived T cell growth factor (TSTGF). I. Functional distinction of TSTGF from interleukins 2 and 4 and its preferential growth-promoting effect on helper T cell clones. (1987) (23)
SCID (severe combined immunodeficiency) mice as a new system to investigate metastasis of human tumors. (1990) (23)
Developmentally regulated expression of a murine receptor-type protein tyrosine phosphatase in the thymus. (1994) (22)
Identification of IL-7-dependent bone marrow-derived Thy-1-B220- lymphoid cell clones that rearrange and express both Ig and T cell receptor genes. (1992) (22)
Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression. (1998) (22)
cDNA cloning of a novel protein tyrosine phosphatase with homology to cytoskeletal protein 4.1 and its expression in T-lineage cells. (1994) (22)
Cholecystokinin-8-like immunoreactivity in the pre- and post-central gyri of the human cerebral cortex (1984) (22)
CD28 costimulation is required not only to induce IL‐12 receptor but also to render Janus kinases / STAT4 responsive to IL‐12 stimulation in TCR‐triggered T cells (2001) (21)
Immune Dysfunction Expressed Selectively on L3T4+ T Cells in the Tumor‐Bearing State (1990) (21)
CD28 co-stimulatory signals induce IL-2 receptor expression on antigen-stimulated virgin T cells by an IL-2-independent mechanism. (1996) (20)
Property of class I H-2 alloantigen-reactive Lyt-2+ helper T cell subset. Abrogation of its proliferative and IL-2-producing capacities by intravenous injection of class I H-2-disparate allogeneic cells. (1988) (20)
Rapid Growth and Spontaneous Metastasis of Human Germinal Tumors Ectopically Transplanted into Scid (Severe Combined Immunodeficiency) and Scid‐nudestreaker Mice (1991) (20)
Heterogeneity of CD4+ T cells involved in anti-allo-class I H-2 immune responses. Functional discrimination between the major proliferating cells and helper cells assisting cytotoxic T cell responses. (1991) (19)
IFN-α Acts on T-Cell Receptor-Triggered Human Peripheral Leukocytes to Up-Regulate CCR5 Expression on CD4+ and CD8+ T Cells (2001) (19)
Antibody production in mice. I. The analysis of immunological memory. (1969) (19)
Cyclosporin A inhibits late steps of T lymphocyte activation after transmembrane signaling. (1987) (18)
B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state. (1998) (18)
Capacities of a Newly Established Thymic Stromal Cell Clone to Express la Antigens and to Produce Interleukin‐6, Colony‐Stimulating Factor, and Thymic Stroma‐Derived T‐Cell Growth Factor (1989) (18)
The mechanism of tolerance induction in thymus-derived lymphocytes; I. intracellular inactivation of hapten-reactive helper T lymphocytes by hapten-nonimmunogenic copolymer of D-amino acids (1975) (18)
Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigen-presenting cells. (2000) (18)
Ontogeny of neuropeptides in the nucleus ventromedialis hypothalami of the rat: an immunohistochemical analysis. (1984) (18)
The augmentation of tumor-specific immunity by virus help (1986) (18)
Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies. (1985) (17)
Development and Recognition of the Transformed Cell (1987) (17)
Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells. (1980) (17)
Do Structural Changes of T Cell Receptor Complex Occur in Tumor‐bearing State? (1995) (17)
Thymic stroma-derived T cell growth factor (TSTGF). IV. Capacity of TSTGF to promote the growth of L3T4- Lyt-2- thymocytes by synergy with phorbol myristate acetate or various IL. (1989) (17)
Identification of two distinct factors, B151-TRF1 and B151-TRF2, inducing differentiation of activated B cells and small resting B cells into antibody-producing cells. (1986) (17)
Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response. (1992) (17)
Induction of anti-allo-class I H-2 tolerance by inactivation of CD8+ helper T cells, and reversal of tolerance through introduction of third- party helper T cells (1990) (16)
IMMUNOLOGICAL TOLERANCE IN BONE MARROW-DERIVED LYMPHOCYTES (1974) (16)
Anti–HER-2/neu Immune Responses Are Induced before the Development of Clinical Tumors but Declined following Tumorigenesis in HER-2/neu Transgenic Mice (2004) (16)
IL-5 up-regulates but IL-4 down-regulates IL-2R expression on a cloned B lymphoma line. (1990) (16)
A mechanism underlying STAT4-mediated up-regulation of IFN-gamma induction inTCR-triggered T cells. (2004) (16)
Immunoregulation in the rat: cellular and molecular requirements for B cell responses to types 1, 2, and T-dependent antigens. (1985) (15)
An in vitro model for cyclosporin A-induced interference of intrathymic clonal elimination (1990) (15)
Abrogation of the capacity of delayed-type hypersensitivity responses to alloantigens by intravenous injection of neuraminidase-treated allogeneic cells. (1987) (15)
SUPPRESSION OF ALLOGRAFT RESPONSES BY COMBINING DONOR ALLOANTIGEN‐SPECIFIC INTRAVENOUS PRESENSITIZATION WITH SUBOPTIMAL DOSES OF FK506 (1993) (15)
Instability of assembled T-cell receptor complex that is associated with rapid degradation of zeta chains in immature CD4+CD8+ thymocytes. (1992) (15)
Preferential generation of killer or helper T-lymphocyte activity directed to the tumour-associated transplantation antigens. (1976) (15)
Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses. (1986) (15)
Immunologic characterization of tumor-associated transplantation antigens on MM102 mammary tumor eliciting preferentially helper T cell activity. (1978) (15)
Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models. (2000) (14)
[Immunological memory cells]. (1969) (14)
A role for endogenous IL‐12 in tumor immunity: IL‐12 is required for the acquisition of tumor‐migratory capacity by T cells and the development of T cell‐accepting capacity in tumor masses (2002) (14)
Antibody against T cell-replacing factor acceptor site(s) augments in vivo primary IgM responses to suboptimal doses of heterologous erythrocytes (1981) (14)
Selective elimination of a B cell subset having acceptor site(s) for T cell-replacing factor (TRF) with biotinylated antibody to the acceptor site(s) and avidin-ricin A-chain conjugate. (1984) (14)
Tolerance Induction of Alloreactivity by Portal Venous Inoculation with Allogeneic Cells Followed by the Injection of Cyclophosphamide (1988) (14)
Functional characterization of the killer-helper factor responsible for the induction of cytotoxic T lymphocytes from thymocytes, and evidence for the nature of this factor as distinct from T cell-replacing factor (TRF) in regard to B cell triggering. (1981) (13)
Establishment of three PPD-reactive helper T cell clones with distinct functions in B cell activation. (1984) (13)
Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells. (1986) (13)
The anti-tumor effects of IL-12 involve enhanced IFN-gamma production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-gamma production. (1997) (13)
Cell interactions between histoincompatible T and B lymphocytes. V. Failure of histoincompatible T cells to interfere with physiologic cooperation between syngeneic T and B lymphocytes. (1974) (13)
Pre-B cells adhere to fibronectin via interactions of integrin α5/αv with RGDS as well as of integrin α4 with two distinct V region sequences at its different binding sites (1994) (13)
Expression of H-2 antigens and inducibility of antitumor immune responses in various tumor cell clones established from methylcholanthrene-induced fibrosarcomas. (1986) (13)
High plasma cholecystokinin response following ingestion of test meal by patients with non-insulin dependent diabetes mellitus (1986) (13)
Generation of cytotoxic T lymphocytes from thymocyte precursors to trinitrophenyl-modified self antigens. I. Requirement of both killer-helper factor(s) and interleukin 2 for CTL generation from a subpopulation of thymocytes. (1986) (13)
IFN-alpha acts on T-cell receptor-triggered human peripheral leukocytes to up-regulate CCR5 expression on CD4+ and CD8+ T cells. (2001) (13)
Detection and characterization of idiotype-specific enhancing cells generated in mice immunized with idiotype. (1982) (13)
T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses. (1985) (13)
Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. II. Selective inactivation of hapten-reactive suppressor T cells by hapten-nonimmunogenic copolymers of D-amino acids, and its application to the study of suppressor T-cell effect on helper T-cell development (1977) (13)
THE LYMPHOID CELL POPULATIONS REQUIRED FOR INDUCTION OF TOLERANCE OF DIFFERENT SUBSETS OF ALLOANTIGEN‐REACTIVE T CELLS (1991) (12)
Synergy between CD28 and CD9 costimulation for naive T-cell activation. (1997) (12)
Direct recognition of rat MHC antigens on rat antigen-presenting cells by mouse CD4+ and CD8+ T cells and establishment of T cell clones exhibiting a direct recognition pathway. (1997) (12)
Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1. (1985) (12)
Localization of PTP-FERM in nerve processes through its FERM domain. (2002) (11)
Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. II. Immunohistochemical studies on the thyroiditis lesion. (1989) (11)
REDISTRIBUTION OF CALDESMON AND TROPOMYOSIN ASSOCIATED WITH CONCANAVALIN A RECEPTOR CAPPING ON SPLENIC T-LYMPHOCYTES (1987) (11)
Relationship between carcinoembryonic antigen and major histocompatibility antigens on cultured human carcinoma cells. (1980) (11)
A novel function of B lymphocytes from normal mice to suppress autoimmunity in (NZB × NZW)F1 mice (2000) (11)
A Defect in Cell–to–cell Adhesion via Integrin–Fibronectin Interactions in a Highly Metastatic Tumor Cell Line (1997) (11)
Antibody production in mice. II. The mechanism of antigenic stimulation in the secondary immune response. (1971) (10)
Selective suppression of host T cell and macrophage activities during 7,12-dimethylbenz[a]anthracene-induced carcinogenesis. (1982) (10)
Inhibitory effect of tumor-bearing state on the generation of in vivo protective immune T cells in a syngeneic murine tumor system. (1977) (10)
Immune maturation of T lymphocytes: sequential changes in the functional specificity and apparent affinity of hapten-reactive helper T cells during an immune response. (1976) (10)
Effector cell analysis of tumor cell rejection in vivo in two syngeneic tumor systems exhibiting distinct in vitro cytotoxic mechanisms. (1984) (10)
Characterization of defectiveness in endogenous antigen presentation of novel murine cells established from methylcholanthrene-induced fibrosarcomas. (1995) (10)
The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo. (1986) (10)
Antibody production in mice. V. The suppressive effect of anti-carrier antibodies on cellular cooperation in the induction of secondary anti-hapten antibody responses. (1973) (10)
Mediation of in vivo Tumor‐neutralizing Activity by Lyt‐2+ as Well as L3T4+ T Cell Subsets*1 (1988) (10)
Tumor Vaccination That Enhances Antitumor T-Cell Responses Does Not Inhibit the Growth of Established Tumors Even in Combination With Interleukin-12 Treatment: The Importance of Inducing Intratumoral T-Cell Migration (2000) (9)
Non-H-2-linked genetic regulation of cytotoxic responses to hapten-modified syngeneic cells. I. Non-H-2-linked Ir gene defect expressed on T cells is not predetermined at the stage of bone marrow cells. (1986) (9)
Acceptor site(s) for T cell-replacing factor (TRF) on B lymphocytes. I. TRF-substituting activity of anti-TRF acceptor site(s) antibody in the triggering of B cells. (1982) (9)
Role of a thymic stromal cell clone in inducing the stage-specific differentiation of various subpopulations of double negative thymocytes. (1991) (9)
Antibody production in mice. VI. Effect of anti-carrier antibody on cellular co-operation in the primary anti-hapten antibody response. (1974) (9)
Analysis of the Mobility of Signaling Molecules in Lymphocytes Using Fluorescence Photobleaching Techniques (2003) (9)
Disparate functions of I‐A and I‐E molecules on B cells as evidenced by the inhibition with anti‐I‐A and anti‐I‐E antibodies of polyclonal B cell activation (1989) (9)
Demonstration of up-regulated IL 2 receptor expression on an in vitro cloned BCL1 subline. (1987) (9)
Polyclonal B cell activation by B cell differentiation factor B151-TRF2. I. Involvement of self-Ia recognition process mediated by B cells. (1986) (9)
Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells. (1997) (9)
Cell-cell interaction in graft rejection responses: induction of anti- allo-class I H-2 tolerance is prevented by immune responses against allo-class II H-2 antigens coexpressed on tolerogen (1992) (8)
IMMUNOLOGICAL TOLERANCE IN BONE MARROW-DERIVED LYMPHOCYTES (1974) (8)
Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells. (1984) (8)
Pillars article: Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 1982. 155: 914-923. (2013) (8)
Differential involvement of a Fas-CPP32-like protease pathway in apoptosis of TCR/CD9-costimulated, naive T cells and TCR-restimulated, activated T cells. (1998) (8)
The role of Ia antigens in the activation of T cells by concanavalin A: an evidence for the species restriction between T cells and accessory cells. (1981) (8)
Modulation of B-cell abnormalities in lupus-prone (NZB x NZW)F1 mice by normal bone marrow-derived B-lineage cells. (1995) (8)
Separation of the Tumor Rejection Antigen of Rous Sarcoma Virus‐induced Murine Fibrosarcoma (1988) (8)
Mechanisms for Recognition of Tumor Antigens and Mediation of Anti‐tumor Effect by Noncytolytic Lyt‐2+ T Cell Subset*1 (1988) (8)
Model for clonal elimination in the thymus. (1989) (8)
A caspase inhibitor protects thymocytes from diverse signal-mediated apoptosis but not from clonal deletion in fetal thymus organ culture. (1998) (8)
Preventive effect of hapten-reactive thymus-derived helper lymphocytes on the tolerance induction in hapten-specific precursors of antibody-forming cells. (1975) (7)
Involvement of I-A-restricted B-B cell interaction in the polyclonal B cell differentiation induced by lipopolysaccharide. (1990) (7)
Cluster formation among small resting B lymphocytes leading to B cell activation. (1989) (7)
Selective inhibition of T lymphocyte repopulation of lymphoid organs as a mechanism of immunosuppression in tumor‐bearing mice (1976) (7)
The role of hapten-reactive T lymphocytes in the induction of autoimmunity in mice. I. Establishment of the experimental conditions for the termination of immunological tolerance to human gamma globulin. (1976) (7)
Tolerance induction of allo-class I H-2 antigen-reactive Lyt-2+ helper T cells and prolonged survival of the corresponding class I H-2-disparate skin graft. (1989) (7)
X-linked recessive inheritance of a defective responsiveness to T-cell-replacing factor in DBA/2Ha mice. (1981) (7)
Differential effects of N-acetyl-l-cysteine on IL-2- vs IL-12-driven proliferation of a T cell clone: implications for distinct signalling pathways. (2000) (7)
Antibody production in mice. 3. The suppressive effect of antibody on the initiation of secondary immune response. (1971) (7)
The mechanism of specific suppression in effector T cell clones against tumor-associated transplantation antigens. (1981) (7)
Immunosuppressive activity of chromatin fraction derived from nuclei of Ehrlich ascites tumor cells. (1972) (6)
Immunological Properties of Fc Receptor on Lymphocytes (1981) (6)
II. FAILURE OF PHYSIOLOGIC COOPERATIVE INTERACTIONS BETWEEN T AND B LYMPHOCYTES ~ROM ALLOGENEIC DONOR STRAINS IN HUMORAL RESPONSE TO HAPTEN-PROTEIN CONJUGATES* (1973) (6)
Ia-restricted B-B cell interaction. I. The MHC haplotype of bone marrow cells present during B cell ontogeny dictates the self-recognition specificity of B cells in the polyclonal B cell activation by a B cell differentiation factor, B151-TRF2. (1987) (6)
Selective expression of paternal human major histocompatibility antigens on the surface of hydatidiform mole cells. (1978) (6)
Acceptor site(s) for T cell-replacing factor (TRF) on B lymphocytes. II. Activation of B cells by cross-linkage or aggregation of the TRF acceptor molecule. (1982) (6)
B cell growth and differentiation activity of a purified T cell-replacing factor (TRF) molecule from B151-T cell hybridoma. (1985) (6)
Identification and characterization of IL-2 hyper-responsive NZB/WF1 CD5- B cells. (1994) (6)
Distribution of neuropeptides in the hypothalamo-hypophyseal system in the rat: an immunohistochemical observation. (1984) (6)
The role of hapten-reactive T lymphocytes in the induction of autoimmunity in mice. II. Termination of self-tolerance to erythrocytes by immunization with hapten-isologous erythrocytes. (1976) (6)
The development of peritumoral stroma required for IL-12 induced tumor regression depends on the T cell/IFN-gamma-involving host-tumor interaction. (2000) (6)
Selective Suppression of the Generation of Anti‐tumor L3T4+ but Not of Lyt‐2+ T Cell‐mediated Immunity in the Tumor‐hearing State (1988) (6)
B-B cell interaction involved in polyclonal B cell activation is restricted by I-A but not by I-E molecules. (1990) (6)
Suppression of allograft responses by combining alloantigen-specific i.v. pre-sensitization with suboptimal doses of rapamycin. (1994) (6)
Cellular mechanisms of tumor rejection in vivo and enhanced induction of anti tumor protective immunity applicable to tumor-specific immunotherapy. (1988) (5)
Proliferation and differentiation of immature thymocytes induced by a thymic stromal cell clone. (1990) (5)
Prophylactic effect of BCG cell-wall skeleton on the tumor induction by 7,12-dimethylbenz[a]anthracene in mice: strain difference. (1979) (5)
Subunit composition of the pre‐T‐cell receptor complex analysed by monoclonal antibody against the pre‐T‐cell receptor α chain (1997) (5)
Helper activity of tuberculin-reactive cells on anti-hapten antibody response. (1972) (5)
T‐T Cell Interaction in the In Vitro Induction of Delayed‐Type Hypersensitivity (DTH) Responses: Demonstration of Vaccinia Virus‐Reactive Helper T Cell Activity Involved in Enhanced Induction of DTH Responses (1985) (5)
Marked depression of brain cholecystokinin and vasoactive intestinal polypeptide levels in Eck fistula dogs (1989) (5)
Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers. (1986) (5)
Interleukin-1 restores the impaired cytotoxic T lymphocyte generation in beige mutant mouse. (1984) (5)
The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives (2004) (5)
Lymphokine-regulated differential expression of mRNA for p75kDa-IL-2R and p55kDa-IL-2R in a cloned B lymphoma line (BLC1-CL-3 cells). (1990) (5)
Suppressive versus augmenting effect of the same pretreatment regimen in two murine tumor systems with distinct effector mechanisms. (1978) (5)
Type II collagen-induced murine arthritis. II. Genetic control of arthritis induction is expressed on L3T4+ T cells required for humoral as well as cell-mediated immune responses to type II collagen. (1989) (5)
Augmentation of auto-anti-idiotypic antibody production by hapten-reactive helper T lymphocytes. (1980) (5)
Effects of hapten epitope structure and hapten-self conjugation pattern on T cell specificity and Ir gene control in hapten-self cytotoxic and helper T cell responses. (1984) (5)
The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo. (1986) (5)
Genetic control of hapten-reactive helper T-cell responses and its implications for the generation of augmented antitumor cytotoxic responses. (1985) (5)
T-cell-derived factor B151-TRF1/IL-5 activates blastoid cells among unprimed B cells to induce a polyclonal differentiation into immunoglobulin M-secreting cells. (1988) (5)
Thymic stromal cells eliminate T cells stimulated with antigen plus stromal Ia molecules through their cross-talk involving the production of interferon-gamma and nitric oxide. (1994) (5)
Studies on macrophage-activating factor (MAF) in antitumor immune responses (1987) (5)
Evidence for existence of two distinct TNP-Ficoll-responsive B cell subpopulations preferentially reactive either to a T cell-replacing factor (B151-TRF) or to a signal from accessory cells. (1986) (5)
Suppressed activity of thymus-derived cell in tumor-bearing host. (1972) (5)
Suppression of Anti‐tumor CD4+ T Cell Responsiveness in the Tumor‐bearing State and Its Recovery in in vitro Culture Free of Tumor Burden (1993) (4)
Tumor-specific immunotherapy by active immunization with haptenic muramyl dipeptide derivative-coupled tumor cells. (1987) (4)
Thymic Stroma‐Derived T Cell Growth Factor (TSTGF): III. Its Ability to Promote T Cell Proliferation Without Stimulating Interleukin 2‐ or 4‐Dependent Autocrine Mechanism (1990) (4)
REGULATORY FUNCTIONS OF HAPTEN-REACTIVE HELPER (1977) (4)
Failure of immunological memory in DMBA-treated mice. (1972) (4)
Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden (2005) (4)
Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells (2005) (4)
Dystrophic axons in the nucleus gracilis of the normal rat containing cholecystokinin-like immunoreactivity (1985) (4)
Thymic Stroma‐Derived T‐Cell Growth Factor (TSTGF): II. Biochemical and Functional Characterization (1988) (4)
Requirement of the thymus for the recovery of anti-alloantigen helper T cells from tolerance induced by intravenous presensitization with allogeneic cells. (1990) (4)
The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: Role of antigen-presenting cells and their surface class I and class II H-2 molecules (2004) (4)
The restoration of suppressed T cell activities induced by 7,12-dimethylbenz[a]anthracene with an anti-tumor immunomodulator, BCG-cell wall skeleton. (1982) (4)
Mechanism of the inhibition of T cell activation by immunosuppressant FK506 (1988) (3)
Meal-stimulated cholecystokinin release and exocrine pancreatic secretion in dogs (1988) (3)
Polyclonal B cell activation by a B cell differentiation factor, B151-TRF2. II. Evidence for interaction of B151-TRF2 with glycoprotein on B cell membrane via recognition of terminal N-acetyl-D-glucosamine residue(s). (1986) (3)
Prevention of tumor metastasis after surgical removal of primary tumor by using in vitro activated macrophages. (1985) (3)
The augmenting effect of antibody on the induction of an immune response. (1972) (3)
Response to IL-18 γ and Produce IFN-T Cell Subsets to Express IL-18 Receptor − CD 8 − , and CD 4 + , CD 8 + Differential Capacities of CD 4 (1998) (3)
Studies on the recovery from tolerance to tumor antigens (1987) (3)
The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives (1987) (3)
Cytotoxic T lymphocyte unresponsiveness induced by prolonged treatment with immobilized anti-CD3 antibody. Association of impairment of cytolytic activity with temporary depletion of intracellular protein kinase C. (1989) (3)
The cellular and molecular basis of the Lyt‐1+2− T cell‐mediated tumor‐eradicating mechanism in vivo (1986) (3)
Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity. (1987) (3)
T-cell-replacing factor and its acceptor site on B cells: molecular properties and immunogenetic aspects. (1985) (3)
Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity (1986) (3)
The Tumor Rejection Antigen Separated from Rous Sarcoma Virus‐induced Murine Fibrosarcoma Exhibits a Molecular Weight of Approximately 60 kD but Differs from Functional pp60src (1989) (2)
Rafts by Enhancing the Association of TCR with in T Cell Rafts Induce T Cell Costimulation Non-CD28 Costimulatory Molecules Present (2000) (2)
Studies on the recovery from tolerance to tumor antigens (2004) (2)
Role of L3T4 Antigen in the Activation of Various Functions of Lyt‐1+2‐ T Cells against Vaccinia Virus (1986) (2)
Stimulatory effects of bombesin on plasma trypsin release and exocrine pancreatic secretion in dogs. (1990) (2)
Prevention of suppression of alloreactive capacity following intravenous injection of neuraminidase-treated allogeneic cells by co-injection of agents competing for asialoglycoprotein receptor. (1988) (2)
Release of 3,5,3′-triiodothyronine, thyroxine and thyroglobulin from TSH-stimulated mouse thyroids in the perifusion system (1988) (2)
Role of N-acetyl-D-galactosamine residue on B151K12-derived T cell-replacing factor (B151-TRF) molecule in B cell-receptor binding and -stimulating activity. (1985) (2)
Antigen‐presenting Cells Constitutively Bind Tumor Antigens in the Tumor‐bearing State in vivo to Construct an Effective Immunogenic Unit (1991) (2)
Purification and characterization of immunosuppressive factor derived from human trophoblast and malignant cells (1983) (2)
Regulatory Mechanism of Reagin Production in Mice at the T Cell Level (1979) (2)
Trophoblast-derived immunoreguratory factor (1983) (2)
The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives (2004) (2)
Polyclonal B-cell activation by a B-cell differentiation factor B151-TRF2. IV. B151-TRF2-responsive F1 B cells consist of two separate populations capable of recognizing only one of the parental I-A products expressed on B cells. (1987) (1)
[Biochemical characterization of tumor rejection antigen (TRA) and genetic control in anti-TRA immune responses]. (1989) (1)
Thymic stroma-derived T cell growth factor: its role in the growth of immature thymocytes and T cell repertoire selection. (1988) (1)
Preventive effect of Propionibacterium acnes on metastasis in mice rendered tolerant to tumor-associated transplantation antigens. (1980) (1)
Mouse CD4 and CD8 T-cell clones that recognize xeno-antigens directly on xeno-antigen presenting cells in xeno MHC-restricted ways. (1997) (1)
Immunosuppressive T cell circuit induced by trophoblast-derived Fc-binding protein (1983) (1)
Tolerance induction in tumor-specific effector T cells by presensitization with tumor antigens via the intragastric route. (1984) (1)
MOLECULAR MECHANISMS UNDERLYING T CELL MIGRATION RESPONSIBLE FOR IL-12-INDUCED TUMOR REGRESSION (1999) (1)
Molecular mechanisms underlying IFN-y-mediated tumor growth inhibition induced during tumor immunotherapy with rlL-12 (2005) (1)
Ultrastructure of murine tumour cell lines defective in MHC class I expression before and after interferon-gamma treatment. (1998) (1)
Promoter Activation Non-CD 28 Costimulatory Molecules to IL-2 Differential Contribution of CD 28 Versus Molecular Mechanisms Underlying (2002) (1)
Inhibitory effect of Propionibacterium acnes-activated macrophages on the tumor metastasis enhanced by tumor-specific immunosuppression. (1981) (1)
[Major histocompatibility complex and localization and functions of immune response genes]. (1978) (1)
Tumor‐specific T Cell Lines: Capacity to Proliferate and Produce Interleukin 2 in Response to Various Forms of Tumor Antigens (1992) (1)
T cell responses in the induction of immune resistance against syngeneic murine myelomas. (1978) (1)
Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion. (1993) (1)
Effect of helper T cells on prevention of tolerance induction in effector T cells responsible for syngeneic tumor immunity. (1982) (1)
Immunogenetic Analysis of Tolerance Induction in Anti‐Alloantigen Delayed Type Hypersensitivity Responses by Portal Venous Pre‐Inoculation with Allogeneic Cells (1987) (1)
Proliferative response of T lymphocytes to allogeneic tumor without generation of killer T lymphocytes in the presence of Ehrlich ascites tumor fluid. (1976) (1)
Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. (1988) (1)
A novel immunization procedure for production of anti-testosterone and anti-5 alpha-dihydrotestosterone antisera of low cross-reactivity. (1980) (1)
Detection of the dominant expression of the TEPC-15 idiotypic determinant(s) on phosphorylcholine-specific suppressor T lymphocytes in vitro. (1981) (1)
Enhancement of lethal metastasis of plasmacytoma in mice rendered tolerant to tumor-associated transplantation antigens. (1980) (1)
IMMUNOLOGICAL FUNCTION AND BIOLOGICAL CHARACTERIZATION OF T CELL-REPLACING FACTOR AND ITS ACCEPTOR SITE(S) ON B CELLS (1983) (1)
B CELL GROWTH FACTOR DISTINCT FROM INTERLEUKIN 2 915 (2003) (0)
[Antineoplastic effects of interleukin-12]. (1995) (0)
Salivary gland chromosomes of drosophila immigrans (1987) (0)
Morphological studies of CCK-8 in the spinal cord. (1983) (0)
Immunological properties of Fc receptor on lymphocytes. 9. Functional analysis of FcR gamma+ and FcR gamma- lymphocytes in IgE antibody responses. (1981) (0)
[Immune-complex formation and antibody production]. (1970) (0)
Rafts in Resting T Cells Glycolipid-Enriched Microdomains in Lipid Protein / Phosphoprotein Associated with Phosphorylation of Csk-Binding Cutting Edge : Fyn Is Essential for Tyrosine (2002) (0)
Cellular site of action of various adjuvants in the immune system. Abstr. (1973) (0)
Diurnal profile of pancreatic exocrine secretion and plasma levels of gut hormones (Cholecystokinin and Pancreatic Polypeptide) (1987) (0)
[Future perspectives on tumor-specific immunotherapy using hapten-reactive T cell activity]. (1989) (0)
A physiological interaction of T cells and Mac-1+ cells is not necessary to induce the selective loss of CD3zeta chains in tumor-bearing state. (1995) (0)
Thymic stroma-derived T-cell inhibitory factor (TSTIF). 2: TSTIF acts on the antigen-presenting cell to inhibit antigen-stimulated T-cell proliferation. (1993) (0)
GENERATION OF MARROW STROMAL CELLS PROVIDING HEMATOPOIETIC MICROENVIRONMENT IN ECTOPIC BONE TISSUE PROVOKED BY OSTEOGENIC FACTOR (1989) (0)
T Cell Responses in the Induction of Immune Resistance against Syngeneic Murine Myelomas (Proceedings of the 40 General Meeting of the Japan Hematological Society-2-) -- (Immunotherapy of Hematological Malignancies and Its Fundamental Basis(Symposium)) (1978) (0)
[Role of immune complex and immunogenicity]. (1975) (0)
Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin. (1994) (0)
Non-chromatographic radioimmunoassays for testosterone and 5 alpha-dihydrotestosterone in adult female serum using antisera with low cross-reactivities. (1980) (0)
Expression of differentiation antigens cross-reactive with Ly-6.2 alloantigens on MM102 mouse mammary tumor cells. (1982) (0)
The process of GEM/Raft-mediated lymphocyte activation (1999) (0)
TCR-Restimulated , Activated T Cells TCR / CD 9-Costimulated , Naive T Cells and Protease Pathway in Apoptosis of Differential Involvement of a Fas-CPP 32-Like (1998) (0)
[Mechanism of antigenic recognition in secondary immune response]. (1969) (0)
Evidence of direct recognition subset in xeno-reactive helper T cells. (1996) (0)
[Identification of autoantibody-inductive B cell-stimulation factor and gene regulation of an MHC-linked B cell response]. (1988) (0)
Cell-cell interaction in graft-rejection responses: breakdown of tolerance to allo-class I H-2 antigens by helper T cells against other histocompatibility antigens simultaneously expressed on a graft. (1991) (0)
Partial Reversal of DNP-Specific Tolerance Induced in Vivo With Immunogenic DNP Proteins by Serial Adoptive Transfer (0)
Ocytes. II. Selective inactivation of hapten-reactive suppressor t cells by hapten-nonimmunogenic copolymers of d-amino acids, and its application to the study of suppressor t-cell effect on helper t-cell development. (1977) (0)
Application of T Cell—T Cell Interaction to Enhanced Tumor-Specific Immunity Capable of Eradicating Tumor Cells in Vivo (1987) (0)
OV-HM, Meth A, or MCH-1-A1 tumor induced complete regression of CSA1M and OV-HM tumors but induced only a slight growth inhibition (2006) (0)
I. EVIDENCE FOR AN INTRACELLULAR MECHANISM OF INACTIVATION OF HAPTEN-SPEcIFIC PRECURSORS OF ANTIBODY-FoRMING CELLS* BY DAVID H. KATZ, TOSHIYUKI HAMAOKA,:~ AND BARUJ BENACERRAF (2003) (0)
Role of T cell-replacing factor (TRF) produced by monoclonal T-cell hybridoma in B-cell differentiation (1982) (0)
[Regulatory effect of antibody formation on the antigen recognition mechanism]. (1971) (0)
The mechanism of tolerance induction of tumor-specific delayed-type hypersensitivity responses by intravenous inoculation of tumor cells. (1985) (0)
The suppressive effect of antibodies on cellular cooperation. (1974) (0)
Reversible CD8 expression induced by common cytokine receptor γ chain-dependent cytokines in a cloned CD4+ Th1 cell line (2002) (0)
[Establishment of cholecystokinin specific radioimmunoassay-determination of CCK in human plasma]. (1983) (0)
~I. EFFECTS OF ALLOGENEIC CELL INTERACTIONS AND ENZYMATIC DIGESTION WITH TRYPSIN ON INACTIVATED HAPTEN-SPECIFIC PRECURSORS OF ANTIBODY-FORMING CELLS* BY TOSHIYUKI HAMAOKA AND DAVID H. KATZ (0)
[Analysis with immunoreactive CCKs and bioactive CCKs in rat duodenum and brain]. (1989) (0)
Active muramylpeptidester derivatives. (1985) (0)
Cholecystokinin system in the rat piriform cortex (1983) (0)
Suppressive effect of portal venous inoculation with tumor cells on the anti-tumor immune potential. (1987) (0)
[A new immunization procedure for production of specific antibody with low cross-reactivity for immunoassay. Artificial selection and expansion of clones producing site-specific antibody]. (1982) (0)
Cardiovascular regulation of neurokinin B in the central nervous system of rats (1990) (0)
Reversible CD8 expression induced by common cytokine receptor gamma chain-dependent cytokines in a cloned CD4(+) T(h)1 cell line. (2002) (0)
Cell-mediated T lymphocyte responses against syngeneic cells modified with amino-reactive hapten (AED-NH2): H-2Dk serves as an element for cell-mediated lympholysis to amino-reactive hapten (AED-NH2)-modified self. (1985) (0)
[Immunological technology]. (1982) (0)
A Site-specific Antibody Produced with a Novel Immunization Procedure by Induction of Tolerance to Cross-reacting Determinants and Its Utilization in Clinical Research (1987) (0)
AUGMENTATION OF TUMOR-SPECIFIC IMMUNITY BY T-T CELL INTERACTION AND ITS APPLICATION TO TUMOR METASTASIS INHIBITION (1982) (0)
Comparative studies on B cell reactivities in two X-linked immunodeficient mice to the B cell-stimulating factors. (1986) (0)
Cellular Cooperation on Anti-Hapten antibody Response (1972) (0)
The role of I-region associated antigen (Ia)-bearing accessory cells in the generation of cytotoxic T cells in a subpopulation of thymocytes. (1986) (0)
Antibody Production inMice V.THE SUPPRESSIVEEFFECTOFANTI-CARRIERANTIBODIES ON CELLULAR COOPERATIONINTHE INDUCTIONOF SECONDARY ANTI-HAPTENANTIBODY RESPONSES (1973) (0)
Inhibitory effect of CCA on immunoglobulin-production induced by B 151-TRF2. (1990) (0)
Isolation of soluble immunosuppressive substance(s) from Ehrlich ascites tumor cell nuclei. (1976) (0)
The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens (2004) (0)
Effect of Passive Administration of Alloantiserum Containing Antibody against Putative Acceptor(s) for T Cell‐Replacing Factor (TRF) in the Neonatal Stage on Development of B Cell Activity Responsive to TRF (1986) (0)
[The role of hapten-specific T cells in the induction of autoimmunity and immune resistance against tumor in mice (author's transl)]. (1978) (0)
The Origin of Antibody‐Forming Cells Detected in the Bone Marrow after Thymus‐Independent Antigen‐Stimulation and Abnormality in Migration of B Cells of X‐Linked Immunodeficient CBA/N Mice (1987) (0)
IV. INVOLVEMENT O~' TIlE )~MMUNE RESPONSE (Ir) GENt: IN THE CONTROL OF LYMPHOCYTE INTERACTIONS IN RESPONSES CONTROLLED BS~ TIlE GENE* (1973) (0)
Activation Costimulatory Molecules to IL-2 Promoter Contribution of CD28 Versus Non-CD28 Molecular Mechanisms Underlying Differential (2011) (0)
A novel immunization procedure involving pretreatment with cross-reacting steroid conjugated to a copolymer of D-glutamic acid and D-lysine for production of low cross-reactive antisera. (1980) (0)
Identification of a B cell subset responsive to a T cell-derived lymphokine B151-TRF2 by monoclonal antibody specific for N-acetylglucosamine residue(S) (1988) (0)
InductionofAnti-Allo-Class IH-2 Toleranceby Inactivation ofCD8 + HelperT Cells,and Reversal ofTolerancethroughIntroductionofThird-Party (1990) (0)
A human glioma cell line of a positive immunostaining for somatostatin (1983) (0)
Suppressive Effect of Ultraviolet‐B‐Irradiation of Epidermal Cells on the Induction of Contact Sensitivity (1986) (0)
and Produce IFN- T Cell Subsets to Express IL-18 Receptor - CD8 - Differential Capacities of CD4+, CD8+, and CD4 (2013) (0)
[Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism]. (1984) (0)
TRF-RESPONSIVE B CELLS CONSTITUTE A SUBPOPULATION DISTINCT FROM THE OTHER B CELL SUBPOPULATION (1982) (0)
Establishment of murine macrophage hybridoma clones capable of acquiring tumoricidal activity upon activation with recombinant interferon-γ and lipopolysaccharide (2004) (0)
Antibody response of the tumor-bearing animals. (1965) (0)
Immunochemical studies on taka-amylase A. Kinetic studies on the inhibition of amylase activity by anti-taa antibody. (1967) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Toshiyuki Officer Resi Hamaoka?

Toshiyuki Officer Resi Hamaoka is affiliated with the following schools: